Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

This review highlights the importance of assessing liver inflammation in NAFLD with non-invasive biomarkers, especially in the drug development process, owing to the inaccuracies of liver biopsies. LiverMultiScan’s cT1 emerges as a robust biomarker that correlates with necroinflammation, fibrosis, and liver-related clinical outcomes, with fewer technical failures than ultrasound-based techniques.